Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33800968)
Watch
English
Anti-androgens and other hormonal therapies for prostate cancer
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
review article
1 reference
stated in
Europe PubMed Central
title
Anti-androgens and other hormonal therapies for prostate cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
main subject
prostate cancer
1 reference
based on heuristic
inferred from title
author name string
Richie JP
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
language of work or name
English
0 references
publication date
1 December 1999
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
published in
Urology
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
volume
54
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
page(s)
15-18
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
issue
6A Suppl
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
cites work
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Megestrol acetate in the treatment of hormone refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Megestrol Acetate for the Prevention of Hot Flashes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ketoconazole and liarozole in the treatment of advanced prostatic cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Secondary hormonal manipulations in hormone refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900449-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0090-4295(99)00449-5
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
PubMed ID
10606279
1 reference
stated in
Europe PubMed Central
PubMed ID
10606279
retrieved
29 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
